The analysis identified that the prioritized tumor types, that is, colorectal cancer, SCCHN, and DLBCL, had tumors with higher levels of CD47-SIRPα and macrophage infiltration, and thus may be suitable targets for BMS-986351 treatment. The gene discussed is SIRPA; the disease is diffuse large B-cell lymphoma.